SCHEMBL2666834

SCHEMBL2666834

CCOC(=O)/C(=N/OC1CCCC1)c1ccc(SC)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.40
MAPT P10636 6/20 0.40
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
LMNA P02545 3/20 0.40
NPSR1 Q6W5P4 2/20 0.40
TSHR P16473 2/20 0.40
KDM4E B2RXH2 3/20 0.40
HRH2 P25021 1/20 0.38
HRH1 P35367 1/20 0.38
ADRB2 P07550 1/20 0.38
RAB9A P51151 2/20 0.37
NPC1 O15118 1/20 0.37
GAA P10253 1/20 0.36
MAPK1 P28482 1/20 0.36
POLB P06746 3/20 0.34
HSD17B10 Q99714 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2666604 0.82 ADRB2 (0.38) ALDH1A1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL2643957 0.82 KMT2A (0.42) ALDH1A1KMT2ASMN1; SMN2LMNARAB9A
SCHEMBL2643960 0.82 KMT2A (0.42) ALDH1A1KMT2ASMN1; SMN2LMNARAB9A
SCHEMBL2643733 0.80 TSHR (0.49) ALDH1A1MAPTKMT2ASMN1; SMN2LMNA
SCHEMBL2643735 0.80 TSHR (0.49) ALDH1A1MAPTKMT2ASMN1; SMN2LMNA
SCHEMBL2140421 0.78 ALDH1A1 (0.44) ALDH1A1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL616073 0.77 ALDH1A1 (0.48) ALDH1A1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL616072 0.77 ALDH1A1 (0.48) ALDH1A1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL2666875 0.75 ALDH1A1 (0.33) ALDH1A1MAPTADRB2POLB
SCHEMBL6025398 0.75 MAPT (0.42) ALDH1A1MAPTMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119626-B2 Oxime derivative and preparations thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-02-21 US disclosed
US-8119626-B2 Oxime derivative and preparations thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-02-21 US disclosed
US-20090291936-A1 OXIME DERIVATIVE AND PREPARATIONS THEREOF SUGAWARA KAZUTOSHI 2009-11-26 US disclosed
US-20090291936-A1 OXIME DERIVATIVE AND PREPARATIONS THEREOF SUGAWARA KAZUTOSHI 2009-11-26 US disclosed
US-7514439-B2 Oxime derivative and preparations thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 US disclosed
US-7514439-B2 Oxime derivative and preparations thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 US disclosed
US-20080132479-A1 Oxime Derivative and Preparations Thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-06-05 US disclosed
US-20080132479-A1 Oxime Derivative and Preparations Thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-06-05 US disclosed
WO-2007007886-A1 AN OXIME DERIVATIVE AND PREPARATIONS THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132479-A1 Oxime Derivative and Preparations Thereof GCK, KHK, GCKR ALDH1A1 1936/4885MAPT 4489/4885MEN1 4054/4885
US-20090291936-A1 OXIME DERIVATIVE AND PREPARATIONS THEREOF GCK, KHK, GCKR ALDH1A1 1936/4885MAPT 4489/4885MEN1 4054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.